SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February, 2022
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x | Form 40-F ¨ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ | No x |
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
Description of Exhibits | |
99.1 | Press Release dated February 7, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
Date: February 7, 2022 | By: | /s/ Vivek Mittal | |
Name: | Vivek Mittal | ||
Title: | Global General Counsel and Compliance Officer |
Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
February 7, 2022
Corporate Relationship Department | National Stock Exchange of India Ltd. |
BSE Limited | “Exchange Plaza” |
Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
Mumbai – 400 001 | Mumbai – 400 051 |
Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
22722037 / 22722039 | 26598238 |
Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on “Dr. Reddy’s Laboratories announces DCGI approval to the single-shot Sputnik Light vaccine in India”
This is for your information.
With regards,
/s/ Vivek Mittal | |
Vivek Mittal | |
Global General Counsel and Compliance Officer |
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd.
CONTACT | ||
DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. |
AMIT AGARWAL amita@drreddys.com |
USHA IYER ushaiyer@drreddys.com |
Dr. Reddy’s Laboratories announces DCGI approval to the single-shot Sputnik Light vaccine in India
· | Sputnik Light is the latest vaccine to be approved in India as part of the national inoculation effort in the fight against COVID-19 |
· | Sputnik Light becomes the second COVID-19 vaccine to be made available in India by Dr. Reddy’s |
Hyderabad, India, February 7, 2022 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) today announced that the Drugs Controller General of India (DCGI) has granted approval to the single-shot Sputnik Light vaccine for restricted use in emergency situation in India.
Sputnik Light is a one-dose vaccine and the same as the first component—recombinant human adenovirus serotype number 26 (rAd26)—of the two-dose Sputnik V vaccine. Following its Phase III clinical trial of the single-shot Sputnik Light vaccine in India, Dr. Reddy’s had submitted its application for approval to the DCGI in December 2021, in addition to data from clinical trial in Russia.
The standalone Sputnik Light vaccine is the latest vaccine to be approved by the DCGI as part of India’s national inoculation effort against COVID-19. Sputnik Light is the second COVID-19 vaccine to be made available in India by Dr. Reddy’s, reaffirming the company’s commitment to explore every avenue in the fight against the pandemic.
Sputnik Light has been approved in over 30 countries around the world including Argentina, UAE, Philippines and Russia. Earlier this year, an independent comparative study conducted by the Spallanzani Institute in Italy showed that Sputnik V demonstrates strong protection against the Omicron variant, with over two times higher virus neutralising activity compared to the Pfizer vaccine1. The data supports the results of the recent laboratory study by the Gamaleya Center demonstrating that Sputnik V induces robust neutralising antibody response to the Omicron variant, further strengthened by Sputnik Light as a booster2.
In September 2020, Dr. Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and distribute the vaccine in India. In April 2021, the DCGI granted approval to the two-dose Sputnik V vaccine for restricted use in emergency situation in India.
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.
1 Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals: https://www.medrxiv.org/content/10.1101/2022.01.15.22269335v1
2 Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant: https://www.medrxiv.org/content/10.1101/2021.12.17.21267976v1
.X_KKUR9!:0[A:VNNGAKV^%> !3N71KWN-#?QO
M7$0U$IE<-)GKM2JT >:$1F30MEC
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M'?UW'4#G,GD\K#(B9WRBJ1*Q-S&A8(6%^T2$N%[[;"I/#X_')R*ME[4Q6
:1>[
M9AOO.&J2GS+[RZN^7.X&